I was a subject in a commercial drug trial performed by a local university to determine the effectiveness of a new drug proposed for potential Alzheimer's patients. They collected a large amount of data over a period of 18 months. This data was archived and could be made available for future studies. I also could be available for further study in conjunction with the previous data.
Developing Data, Tracking Progress
How can we measure progress in Alzheimer’s research recruitment?
As the Alzheimer's research community explores and implements enhanced strategies for recruitment, how can we develop consolidated and localized data on recruitment for Alzheimer's studies, track progress in recruitment and retention of study participants, and tailor strategies based on that data?
Ideas in this area might address:
- Meaningful measures of community engagement
- Approaches to measuring return on investment (ROI)
- Indicators of effectiveness for recruitment strategies
- Recruitment data sharing and harmonization
So many Alz tests include spatial items-which I already stink at. Hopefully tests can be developed utilizing a person's know strengtihs...maybe someone is a sports nut who knows all the baseball stats - test them now and then continue to test to see if they lose knowlege in an area they are good in now. I would do good in verbal and possibly math but am already terrible at spatial ideas and remembering things like ...more »
Develop an app and in addition to the traditional TrialMatch offering, create a platform for lifestyle tracking for all ages. This can be a passive feature (not related to a current research trial). The benefits of this are vast: - It would provide a public health-related service (tracker for food/exercise/mood/lifestyle, etc.) - Would create a much more engaged participation base - Would amass data (with user consent, ...more »
Identify measures of success for a registry and compare the effectiveness of registry models (e.g., national vs. regional or local; Alzheimer’s and dementia vs. “brain health;” on-line vs. in-person; primary care vs. community vs. memory care based, etc.).
To be trite, do not reinvent the wheel. I believe studies of a similar nature have been conducted. Inventory them, determine which were most successful at achieving their desired outcome. Cherry pick the best characteristics from the prior studies. Using the prior studies as models, employ the same techniques to qualify and recruit candidates.
There are no trials in my area, so Trial-Match directed me to online studies. I have participated in all that I could - 3 or 4. They all ask for some medical history and lifestyle (diet, sleep, exercise, smoking) information, and then I complete memory tests. I have noticed that between studies they don't all ask for the same information regarding medical history or lifestyle. Since these are so important to disease ...more »
My colleagues and I are building a community that supports family caregiving, providing education, support and access to providers. Our members will wear health monitoring bands, so their vitals and those of their charges can be monitored, enabling medical professionals to offer guidance in real time. We will also be collecting the data, scrubbed for HIPAA compliance, to researchers to use for development of cures and ...more »
As each person becomes eligible for Medicare, test them for cognitive impairment to establish an individual's benchmark
Just want to know if what I'm talking, doing, etc. Is really helping one into the study. I wouldn't mind staying in it if there was a possibility that it would help someone else even if it didn't help me.
Available Information Technology data is going exponential across the world. Reach up to big data sites and encourage collaboration, Kaiser Permanente, ConsumerLab.com, Major NIH and other health data collectors as examples. Also find alliances outside the U.S. that are collecting & sharing Mega Data on health. Encourage discussions about collaboration and sharing data on multiple important health issues, such as Alzheimer's. ...more »
While totally acknowledging the value of information obtained with high dose radiation (PET-CT scans) to brains of asymtomatic people risks associated with this radiation exposure need to be fully addressed.
People receiving testing followed for possible consequences of the testing. Compensation down the road for consequences of exposure need to be addressed up front.
Develop measures of trust within communities.